Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clonal dynamic changes during the progression of myelodysplastic neoplasms to secondary acute myeloid leukemia: a paired-sample comparison.

Clinical and experimental medicine·2026
Same author

β2-microglobulin is superior to lactate dehydrogenase and bulky disease for risk stratification in diffuse large B-cell lymphoma patients with IPI 1-2.

Annals of hematology·2026
Same author

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Blood advances·2026
Same author

Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.

Leukemia·2026
Same author

Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Ropeginterferon alfa-2b has minimal transplacental passage and breastmilk secretion in pregnant patients with MPN.

Blood advances·2026

Related Experiment Video

Updated: Jul 4, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Primary gastric diffuse large B-cell lymphoma.

Yu-Shin Hung1, Tung-Liang Lin, Ming-Chung Kuo

  • 1Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan, R.O.C.

Chang Gung Medical Journal
|June 24, 2008
PubMed
Summary
This summary is machine-generated.

Chemotherapy (CT) is recommended as the primary treatment for primary gastric large-cell non-Hodgkin's lymphoma (PGL) when diagnosed via endoscopic biopsy. This approach shows comparable survival rates to surgery for PGL.

Related Experiment Videos

Last Updated: Jul 4, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Area of Science:

  • Gastroenterology
  • Oncology
  • Hematology

Background:

  • Optimal treatment for primary gastric large-cell non-Hodgkin's lymphoma (PGL) remains undefined.
  • Emerging evidence suggests organ-preserving strategies may match surgical outcomes.

Purpose of the Study:

  • To evaluate treatment outcomes for PGL.
  • To compare the efficacy of chemotherapy versus surgery in PGL management.

Main Methods:

  • Retrospective review of 88 PGL patients (1995-2003).
  • Analysis of treatment modalities including chemotherapy (CT), radiotherapy (RT), and surgery (ST).
  • Comparison of overall survival (OS) and disease-free survival (DFS) between treatment groups.

Main Results:

  • Complete remission rate was 77.3%.
  • 5-year OS and DFS were 50.0% and 81.6%, respectively.
  • No significant difference in OS or DFS between CT-based and surgery-based treatments.
  • Poor performance status, elevated beta2-microglobulin, and lack of CT adversely impacted OS.

Conclusions:

  • Chemotherapy (CT) is recommended as the primary treatment for PGL when diagnosed via endoscopic biopsy.
  • Treatment approach (CT vs. surgery) did not significantly affect survival outcomes.
  • Prognostic factors like performance status and beta2-microglobulin levels are critical for OS.